Leading regenerative medicine company, BioStem Technologies (OTC: BSEM), has announced that the Center for Medicare Services (CMS) has established national pricing for its product, AmnioWrap2™,…
December 14, 2023
C4 Therapeutics Achieves Positive Data in Multiple Myeloma Trial
C4 Therapeutics, Inc. (Nasdaq: CCCC) has reported positive clinical data from its ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of…
December 13, 2023
PRISM MarketView Biotech in Motion Spotlight: Quoin Receives FDA Clearance for Netherton Syndrome Clinical Optimization Plan
Company continues to report progress with QRX003 clinical data in ongoing trials. Quoin Pharmaceuticals (Nasdaq:QNRX) has received U.S. Food and Drug Administration (FDA) clearance to…
Icosavax, Inc. (Nasdaq: ICVX) will be acquired by AstraZeneca in a deal with a total equity value of up to $1.1 billion. Today, Icosavax also…
The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a Phase 2 clinical trial of oral MYMD-1®…
December 08, 2023
Exscientia Awarded $2.3M Grant for AI-Driven Pandemic Preparedness
Exscientia (Nasdaq: EXAI) has received a $2.3 million grant from Open Philanthropy, a philanthropic funder with several programs in global health and wellbeing. Under this…
December 07, 2023
Solid Biosciences Granted Fast Track Designation for Duchenne Gene Therapy Candidate
Solid Biosciences (Nasdaq: SLDB) has received FDA Fast Track Designation for SGT-003, the company’s next-generation Duchenne muscular dystrophy (DMD) gene therapy candidate. The company will…
December 07, 2023
Aura Biosciences Advances Ocular Melanoma Treatment to Phase 3
Aura Biosciences (Nasdaq: AURA) has dosed the first patient in its global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the…
Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), has initiated the FDA single-site process for its VitaGraft kidney transplant assays. This process is a well-established pathway…
December 06, 2023
Sera Prognostics Soars 205% as Trial is Halted Due to Efficacy
The Pregnancy Company®, Sera Prognostics Inc., (Nasdaq: SERA) has halted its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study…
December 06, 2023
Aussie Biotech Targeting E. Coli and Campylobacter Infections with New Oral Therapeutic
Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in…
December 05, 2023
Clearmind Successfully Treats Cocaine Addiction with Psychedelic Molecule; Shares Soar 70%
Clearmind Medicine Inc. (Nasdaq: CMND) has achieved positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction. The company’s innovative psychedelic molecule, 5-Methoxy-2-aminoindane…